

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 May 2022 (19.05.2022)



(10) International Publication Number
WO 2022/103961 A1

(51) International Patent Classification:

C07K 16/24 (2006.01) C12Q 1/6883 (2018.01)
C07K 16/28 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2021/058979

(22) International Filing Date:

11 November 2021 (11.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/113,657	13 November 2020 (13.11.2020)	US
63/136,153	11 January 2021 (11.01.2021)	US
63/147,165	08 February 2021 (08.02.2021)	US
63/181,074	28 April 2021 (28.04.2021)	US
63/226,032	27 July 2021 (27.07.2021)	US

(71) Applicants: **PROMETHEUS BIOSCIENCES, INC.**

[US/US]; 9410 Carroll Park Drive, San Diego, California 92121 (US). **CEDARS-SINAI MEDICAL CENTER** [US/US]; 8700 Beverly Blvd., Los Angeles, California 90048 (US).

(72) Inventors: **KRUIDENIER, Laurens**; 9410 Carroll Park Drive, San Diego, California 92121 (US). **SABRIPOUR, Mahyar**; 9410 Carroll Park Drive, San Diego, California 92121 (US). **WATKINS, Jeffrey D.**; 9410 Carroll Park Drive, San Diego, California 92121 (US). **DICKERSON, Cindy T.**; 9410 Carroll Park Drive, San Diego, California 92121 (US). **ROJAS, Rafael**; 9410 Carroll Park Drive, San Diego, California 92121 (US). **REISSMAN, Matthew**; 9410 Carroll Park Drive, San Diego, California 92121 (US). **MCNEELEY, Patricia**; 9410 Carroll Park Drive, San Diego, California 92121 (US). **BILSBOROUGH, Janine**; 8700 Beverly Blvd., Los Angeles, California 90048 (US). **MCGOVERN, Dermot P.**; 8700 Beverly Blvd., Los Angeles, California 90048 (US). **LI, Dalin**; 8700 Beverly Blvd., Los Angeles, California 90048 (US).

(74) Agent: **PENNEBAKER, Sara**; Wilson Sonsini, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

(54) Title: METHODS, SYSTEMS, AND KITS FOR TREATMENT OF INFLAMMATORY DISEASES TARGETING TL1A


CDx performance against TL1A ex vivo production assay	
	
% of CDx+ subjects that are TL1A high producers (PPV)	86%
% of TL1A low producers that are CDx- (specificity)	90%
% of cohorts that is CDx+	32%
Enrichment of TL1A high producers in CDx+ subjects	4.6x

FIG. 10

(57) Abstract: Provided are methods, systems, and kits for selecting a subject for treatment with an inhibitor of Tumor necrosis factor-like cytokine 1A (TL1A) activity or expression based on a presence of one or more genotypes associated with a positive therapeutic response to the inhibitor of TL1A. Also provided are methods, systems and kits for detecting the one or more genotypes described herein.

[Continued on next page]

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*